Evan Loh, MD
Evan Loh, MD is Chief Executive Officer of Paratek Pharmaceuticals (NASDAQ: PRTK). Previously, Dr. Loh served as Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, at Pfizer. Dr. Loh joined Pfizer from Wyeth Pharmaceuticals, where he was responsible for global development strategy and clinical operational deliverables. He currently serves on the Board of Directors of Eiger Biopharmaceuticals, Inc. and Windtree Pharmaceuticals, Inc. Dr. Loh served as Chairman of the Antimicrobials Working Group (AWG), an industry leading coalition of biotech companies focused on antimicrobial development from 2019 to 2021, and currently serves on its Executive Committee. Dr. Loh served as a Director on the Board of Nivalis from 2012 until the completion of its sale to Alpine Immunotherapeutics in 2017. Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine. Dr. Loh received his AB from Harvard College and his MD from Harvard Medical School. He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women’s Hospital.